Relmada Therapeutics financials
$3.73−1.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M | -$60.8M | -$15.1M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M | -$59.5M | -$15.0M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 | $-3.81 | $-1.62 |
| EBITDA | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M | -$60.8M | -$15.1M |
| Operating cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M | -$27.8M | -$7.4M |
| Free cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | — | — | -$92.3M |
| Diluted shares | 39.5M | 30.2M | 30.1M | 29.6M | 17.6M | 15.6M | 9.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M | $2.5M |
| Short-term investments | $89.5M | $41.1M | $92.2M | $142.9M | $167.5M | $114.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M | $118.2M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M | $12.6M |
| Shareholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M | $105.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology